Abstract Number: 1640 • ACR Convergence 2024
ACR/EULAR 2022 Classification Criteria Compared to the ACR 1990 Classification Criteria in the ARTESER Registry of Giant Cell Arteritis
Background/Purpose: The diagnosis of giant cell arteritis (GCA) has been guided for years by the ACR 1990 classification criteria but the emergence of the image…Abstract Number: 2111 • ACR Convergence 2024
An International Patient Survey to Identify Candidate Items for Classifying Early-Stage Symptomatic Knee Osteoarthritis
Background/Purpose: Osteoarthritis Research Society International (OARSI) has launched an initiative to develop classification criteria for early-stage symptomatic knee osteoarthritis (EsSKOA). The goal is to establish…Abstract Number: 2196 • ACR Convergence 2024
Identifying Specific Criteria for Juvenile Systemic Sclerosis: A Comparison of Adult and Pediatric Ratings
Background/Purpose: Despite the high morbidity and mortality risk associated with juvenile systemic sclerosis (jSSc), evidence to guide management is limited. No jSSc clinical trials have…Abstract Number: 0543 • ACR Convergence 2023
Sensitivity of the 2019 European Alliance of Associations for Rheumatology /American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population-based Cohort; A Study Set in Norway 2000-2015
Background/Purpose: To diagnose Systemic Lupus Erythematosus (SLE), one must understand the phenotype specter and interpret clinical, serological, radiological, and histopathological data, as well as exclude…Abstract Number: 0711 • ACR Convergence 2023
IgA Vasculitis in a Diverse Adult Patient Population
Background/Purpose: Immunoglobulin-A (IgA) Vasculitis (IgAV) is a small-vessel vasculitis that is primarily diagnosed based on the European League Against Rheumatism (EULAR) criteria. There is limited…Abstract Number: 1059 • ACR Convergence 2023
Identification of Patients with Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis Using Medicare Claims Data
Background/Purpose: Immune checkpoint inhibitor (ICI) associated inflammatory arthritis (ICI-IA) has been suggested to occur in approximately 3-6% of ICI-treated patients with cancer1 but most studies…Abstract Number: 1131 • ACR Convergence 2023
Clinical Phenotypes of IgG4-related Disease in a Multi-ethnic Singapore Cohort
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition that is heterogenous and can result in organ failure. To understand the disease profile of our local…Abstract Number: 1136 • ACR Convergence 2023
Challenges in Diagnosing VEXAS Syndrome: Delayed Diagnosis, Misdiagnosis, and Associations with Specific Gene Mutations
Background/Purpose: The newly described VEXAS syndrome is a very heterogenous disease with rheumatologic and hematologic manifestations, caused by somatic mutations affecting UBA1 gene, that still…Abstract Number: 1175 • ACR Convergence 2023
Inclusion of All Myositis Specific Autoantibodies or Other Rashes Leads to Better Sensitivity but Lower Specificity of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM), collectively known as myositis, are heterogeneous disorders characterized by muscle weakness and muscle inflammation. ACR/EULAR classification criterion for IIM was…Abstract Number: 1228 • ACR Convergence 2023
Validation of the PEDiatric Behçet’s Disease Classification Criteria (PEDBD): An International Consensus-based Approach
Background/Purpose: Behçet's disease (BD) is an autoinflammatory disease characterized by a variable vessel vasculitis. In the past, several criteria have been created for adult BD…Abstract Number: 1545 • ACR Convergence 2023
Validation of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA-associated Vasculitis
Background/Purpose: The early diagnosis of ANCA-associated vasculitis (AAV) and treatment initiation may prevent progression to end organ damage, particularly renal disease. Based on the Vasculitis…Abstract Number: 1901 • ACR Convergence 2023
Which ASDAS-ESR Cut-offs for Disease Activity Correspond to ASDAS-CRP Cut-offs in Axial Spondyloarthritis? – Results from the EuroSpA Collaboration
Background/Purpose: When assessing disease activity in patients with axial spondyloarthritis (axSpA), the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) is recommended over ASDAS…Abstract Number: 1943 • ACR Convergence 2023
IgG4-related Disease: 2010-2022 Case Review and Comparative Evaluation of Diagnostic Criteria
Background/Purpose: IgG4 immunoglobulin-related disease (IgG4-RD) is a rare, systemic immune-mediated fibro-inflammatory process with an unclear etiology and pathophysiology with the capacity of affecting multiple organs.…Abstract Number: 2264 • ACR Convergence 2023
Proposal for Defining Moderate and Severe Activity States in Systemic Lupus Erythematosus. Impact on Flares and Other Outcomes
Background/Purpose: In systemic lupus erythematosus (SLE), there is no definition of states of moderate and severe SLE activity. How these states may influence different disease…Abstract Number: 0108 • ACR Convergence 2023
Decoding Antiphospholipid Syndrome Laboratory Test Outcomes in a Large Multicenter Electronic Health Record Database
Background/Purpose: Electronic health record (EHR) data provide an inexpensive, information-rich tool to study rare diseases like antiphospholipid syndrome (APS). Many such studies rely on structured…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 11
- Next Page »